John G Ullman & Associates Inc Novartis Ag Transaction History

John G Ullman & Associates Inc

  • $649 Million
  • Q3 2024

A detailed history of John G Ullman & Associates Inc transactions in Novartis Ag stock. As of the latest transaction made, John G Ullman & Associates Inc holds 141,466 shares of NVS stock, worth $13.8 Million. This represents 2.51% of its overall portfolio holdings.

Number of Shares
141,466
Previous 177,248 20.19%
Holding current value
$13.8 Million
Previous $18.9 Million 13.77%
% of portfolio
2.51%
Previous 2.99%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
SELL
$106.13 - $120.89 $3.8 Million - $4.33 Million
-35,782 Reduced 20.19%
141,466 $16.3 Million
Q2 2024

Aug 08, 2024
SELL
$92.57 - $107.37 $179,493 - $208,190
-1,939 Reduced 1.08%
177,248 $18.9 Million
Q1 2024

May 06, 2024
SELL
$95.27 - $108.47 $163,197 - $185,809
-1,713 Reduced 0.95%
179,187 $17.3 Million
Q4 2023

Jan 31, 2024
SELL
$92.27 - $101.54 $165,163 - $181,756
-1,790 Reduced 0.98%
180,900 $18.3 Million
Q3 2023

Nov 01, 2023
SELL
$94.73 - $105.13 $212,668 - $236,016
-2,245 Reduced 1.21%
182,690 $18.6 Million
Q2 2023

Aug 21, 2023
SELL
$92.52 - $104.91 $287,737 - $326,270
-3,110 Reduced 1.65%
184,935 $18.7 Million
Q1 2023

May 05, 2023
SELL
$80.03 - $92.81 $493,464 - $572,266
-6,166 Reduced 3.17%
188,045 $17.3 Million
Q4 2022

Feb 08, 2023
SELL
$75.55 - $92.52 $278,250 - $340,751
-3,683 Reduced 1.86%
194,211 $17.6 Million
Q3 2022

Oct 19, 2022
BUY
$74.61 - $87.26 $684,919 - $801,046
9,180 Added 4.86%
197,894 $15 Million
Q2 2022

Jul 27, 2022
BUY
$80.52 - $93.75 $184,793 - $215,156
2,295 Added 1.23%
188,714 $16 Million
Q1 2022

Apr 29, 2022
BUY
$80.11 - $90.62 $655,299 - $741,271
8,180 Added 4.59%
186,419 $16.4 Million
Q4 2021

Jan 26, 2022
BUY
$79.7 - $88.13 $261,814 - $289,507
3,285 Added 1.88%
178,239 $15.6 Million
Q3 2021

Nov 02, 2021
SELL
$81.78 - $95.14 $14,720 - $17,125
-180 Reduced 0.1%
174,954 $14.3 Million
Q2 2021

Jul 23, 2021
SELL
$85.24 - $94.15 $198,609 - $219,369
-2,330 Reduced 1.31%
175,134 $16 Million
Q1 2021

Apr 22, 2021
BUY
$83.5 - $98.47 $587,088 - $692,342
7,031 Added 4.13%
177,464 $15.2 Million
Q4 2020

Feb 05, 2021
BUY
$78.07 - $94.43 $1.48 Million - $1.79 Million
18,948 Added 12.51%
170,433 $16.1 Million
Q3 2020

Nov 06, 2020
SELL
$82.14 - $91.0 $82,140 - $91,000
-1,000 Reduced 0.66%
151,485 $13.2 Million
Q2 2020

Jul 29, 2020
SELL
$80.93 - $91.1 $28,325 - $31,884
-350 Reduced 0.23%
152,485 $13.3 Million
Q1 2020

Apr 14, 2020
SELL
$70.67 - $99.01 $177,735 - $249,010
-2,515 Reduced 1.62%
152,835 $12.6 Million
Q4 2019

Jan 29, 2020
SELL
$84.35 - $95.37 $234,071 - $264,651
-2,775 Reduced 1.75%
155,350 $14.7 Million
Q3 2019

Oct 21, 2019
SELL
$85.54 - $94.26 $57,739 - $63,625
-675 Reduced 0.43%
158,125 $13.7 Million
Q2 2019

Aug 02, 2019
SELL
$75.4 - $92.8 $43,355 - $53,360
-575 Reduced 0.36%
158,800 $14.5 Million
Q1 2019

Apr 30, 2019
SELL
$75.32 - $86.15 $184,533 - $211,067
-2,450 Reduced 1.51%
159,375 $15.3 Million
Q4 2018

Jan 29, 2019
SELL
$73.66 - $82.02 $50,309 - $56,019
-683 Reduced 0.42%
161,825 $13.9 Million
Q3 2018

Nov 02, 2018
SELL
$66.94 - $77.43 $14,057 - $16,260
-210 Reduced 0.13%
162,508 $14 Million
Q2 2018

Jul 23, 2018
BUY
$64.91 - $73.36 $173,634 - $196,238
2,675 Added 1.67%
162,718 $12.3 Million
Q1 2018

Apr 19, 2018
BUY
$70.39 - $84.15 $117,903 - $140,951
1,675 Added 1.06%
160,043 $12.9 Million
Q4 2017

Jan 31, 2018
BUY
$72.33 - $77.64 $18,661 - $20,031
258 Added 0.16%
158,368 $13.3 Million
Q3 2017

Nov 03, 2017
BUY
$74.14 - $77.27 $11.7 Million - $12.2 Million
158,110
158,110 $13.6 Million

Others Institutions Holding NVS

# of Institutions
1,437
Shares Held
131M
Call Options Held
1.12M
Put Options Held
1.83M
View Full List

About NOVARTIS AG

NVS Quotes by TradingView
  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $209B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track John G Ullman & Associates Inc Portfolio

Follow John G Ullman & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of John G Ullman & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on John G Ullman & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email